Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASALT
2023-509458-77-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tocilizumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and Esophageal high-grade dysplasia (HGD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pathological response to chemoradiotherapy according to the Mandard criteria. Planned start Apr 2024; status: authorised.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaEsophageal high-grade dysplasia (HGD)
Beyond the preview
Go deeper on 2023-509458-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509458-77-00.